Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan), also known as 177Lu-PSMA-617, for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have highly expressed prostate-specific membrane antigen (PSMA) and have...
EAST HANOVER, N.J., March 23, 2022 -- Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer ...
FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Targeted Radioligand Therapy for Treatment of Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer FDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the ...
“As a long-standing supplier of n.c.a. lutetium-177 for Pluvicto, we share in the excitement of this approval,” commented Steffen Schuster, Chief Executive Officer of ITM. “At ITM, we strive to provide high-quality radioisotopes no...
(fda) approved radiotherapeutic, pluvicto (lutetium lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer ( mcrpc ) who have been treated with androgen receptor pathway inhibiti...
Treatment with the combination of lutetium Lu 177 vipivotide tetraxetan and enzalutamide led to an improvement in prostate-specific antigen progression-free survival vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer. ...
The Lutetium-177 market exhibits diverse dynamics across various geographies, each shaped by unique regulatory landscapes, healthcare infrastructures, and market demands. In the United States, the strong healthcare system, significant R&D...
It has been approved for use in metastatic castration-resistant prostate cancer (mCPRC) in 3/2022, based on VISION study. The Food and Drug Administration (FDA) label for 177Lu–PSMA requires prior therapy with an androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy as well...
“Neoadjuvant lutetium-PSMA followed by radical prostatectomy appears to be safe in patients with locally advanced high-risk prostate cancer,” concluded Frumer. “While longer oncological outcomes are pending, continence recovery seems to be unaffected by lutetium treatment.” Reference Frumer M, Rosen...
“Those that did complete the surveys generally reported average improvements in bone-metastasis-related pain and ability to function despite that pain,” says Brian D. Gonzalez, PhD.